Applications of 1,3-Dihydro-5-Phenyl-1,4-Benzodiazepin-2-One in Industrial Manufacturing

1,3-Dihydro-5-Phenyl-1,4-Benzodiazepin-2-One serves as a critical intermediate in specialized industries requiring stringent quality and regulatory compliance. Our factory provides this material with controlled impurity profiles, supporting downstream synthesis across pharmaceutical actives, agrochemical development, veterinary preparations, and fine chemical research for advanced material applications.

1. Active Pharmaceutical Ingredient (API) Synthesis: Benzodiazepine Drug Intermediates

This compound is widely used for synthesizing benzodiazepine-based active pharmaceutical ingredients, including sedative-hypnotics and anxiolytics. Pharmaceutical formulators utilize it during multi-stage synthesis of regulated medicines, emphasizing compliance with international GMP standards. Our production maintains batch-to-batch consistency to facilitate its use in regulated therapeutic manufacturing pipelines globally.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU GMP Part II API guidelines
• United States Pharmacopeia (USP) reference for related substances
• EDQM CEP documentation requirements

Typical usage ratio

• Usage in couplings or ring-closure steps typically 0.75–1.25 mol per equivalent final API molecular backbone
• Dosing adjusts based on target molecule complexity and desired impurity profile

Downstream process integration

• Introduced at the fine chemical stage following aromatic substitution reactions
• Engaged in subsequent catalyst-driven transformations (e.g., N-alkylation, halogenation)
• Purified via chromatographic or crystallization steps prior to API finishing
• Undergoes validation in pilot and commercial API production lines

Final product types

• Diazepam, lorazepam, and related benzodiazepine therapeutic tablets/capsules
• Injectable benzodiazepine solutions
• Orally disintegrating benzodiazepine films/granules
• Clinical grade benzodiazepine intermediates for contract API production

2. Agrochemical Intermediate for Crop Protection Formulations

This material acts as a scaffold in the custom synthesis of agrochemicals, especially in research for selective herbicides and pre-emergent weed control agents. Agrochemical manufacturers value its functional group diversity for directed modification, supporting scalable pilot synthesis programs within the EU and Asia-Pacific regulatory environments.

Industry compliance standards

• European Plant Protection Product Regulation (EC) No 1107/2009
• OECD guidelines for testing of chemicals
• China GB/T 1604 pesticide intermediates standards
• ISO 9001:2015 quality systems for process control

Typical usage ratio

• 0.2–0.8 mol per synthetic batch of targeted herbicidal active
• Ratio varies based on specific crop protection compound and modification steps

Downstream process integration

• Direct building block in heterocycle introduction during structure-activity relationship studies
• Fed into alkylation or halogenation steps in research-scale and commercial agrochemical synthesis
• Prepared to technical purity to avoid cross-contamination in multi-purpose plants
• Formulated into test batches for field trial assessment

Final product types

• Pre-emergent and post-emergent herbicide technical concentrates
• Customized weed-control active substances for agricultural markets
• Research compounds for patentable agrochemical development
• Formulated crop protection agents for regulatory submission

3. Veterinary Drug Precursor: Sedative Formulations for Livestock and Companion Animals

Veterinary pharmaceutical producers use this compound as a core intermediate for manufacturing animal sedatives and tranquilizers, essential in veterinary care, animal husbandry, and pre-clinical research. It adheres to country-specific veterinary drug quality standards, ensuring safety and traceability in end-use injectable and oral forms.

Industry compliance standards

• US FDA Code of Federal Regulations (Title 21) for veterinary drugs
• European Medicines Agency (EMA) Veterinary Medicines Regulation (EU) 2019/6
• VICH GL guidelines on Good Manufacturing Practice (GMP) for veterinary products
• Chinese Veterinary Pharmacopoeia (ChP)

Typical usage ratio

• 0.8–1.3 mol per mol of sedative agent, depending on targeted dosage forms
• Adaption by product development teams for animal weight and administration route

Downstream process integration

• Converted via controlled condensation and amination steps within veterinary formulation units
• Blended with pharmacological excipients in validated cleanroom environments
• Processed under strict in-process QC for residue monitoring
• Filled into vials or oral suspensions as per market authorization

Final product types

• Veterinary sedative injection solutions for large and small animals
• Oral veterinary tranquilizer suspensions
• Premix sedative powders for animal feed supplementation
• Research-use bulk intermediates for veterinary API synthesis

4. Fine Chemical Research: Advanced Material Synthesis and Specialty Chemical Development

Academic and industrial R&D departments employ this material as a flexible molecular backbone in the design of new specialty chemicals, catalysts, and supramolecular compounds. Its unique structure enables exploration of novel physical and chemical properties in wear-resistant coatings, polymer additives, and optoelectronic materials, supporting innovation under controlled laboratory and pilot-scale conditions.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• REACH Regulation (EC) No 1907/2006 for chemical registration
• Company-specific ISO 9001:2015 for chemical R&D workflows
• Safety Data Sheet (SDS) requirements under GHS classification

Typical usage ratio

• 0.05–0.5 mol per experimental batch depending on target compound’s scale and complexity
• Ratio tailored to research objectives and downstream material requirements

Downstream process integration

• Initial feed component in exploratory synthesis, often in solution- or solid-phase protocols
• Subjected to further functionalization (e.g., acylation, metallation) by synthetic chemists
• Integrated into property-testing workflows for advanced material development
• Sampled and archived for high-throughput screening pipelines

Final product types

• Prototype wear-resistant polymer coatings
• Novel supramolecular hosts for advanced separation techniques
• Optoelectronic precursor compounds
• Specialty chemical additives for material performance studies